• 1
    Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. Circulation. 2003;107:223225.
  • 2
    Al-Ahmad A, Rand WM, Manjunath G, et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol. 2001;38:955962.
  • 3
    Dunlay SM, Weston SA, Redfield MM, et al. Anemia and heart failure: a community study. Am J Med. 2008;121:726732.
  • 4
    Felker GM, Shaw LK, Stough WG, O'Connor CM. Anemia in patients with heart failure and preserved systolic function. Am Heart J. 2006;151:457462.
  • 5
    Go AS, Yang J, Ackerson LM, et al. Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study. Circulation. 2006;113:27132723.
  • 6
    He SW, Wang LX. The impact of anemia on the prognosis of chronic heart failure: a meta-analysis and systemic review. Congest Heart Fail. 2009;15:123130.
  • 7
    Lindenfeld J. Prevalence of anemia and effects on mortality in patients with heart failure. Am Heart J. 2005;149:391401.
  • 8
    Maggioni AP, Opasich C, Anand I, et al. Anemia in patients with heart failure: prevalence and prognostic role in a controlled trial and in clinical practice. J Card Fail. 2005;119198.
  • 9
    O'Meara E, Murphy C, McMurray JJ. Anemia and heart failure. Curr Heart Fail Rep. 2004;1:176182.
  • 10
    Anand I, McMurray JJ, Whitmore J, et al. Anemia and its relationship to clinical outcome in heart failure. Circulation. 2004;110:149154.
  • 11
    O'Meara E, Clayton T, McEntegart MB, et al. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation. 2006;113:986994.
  • 12
    Felker GM, Gattis WA, Leimberger JD, et al. Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure. Am J Cardiol. 2003;92:625628.
  • 13
    Groenveld HF, Januzzi JL, Damman K, et al. Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol. 2008;52:818827.
  • 14
    Palazzuoli A, Silverberg D, Iovine F, et al. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. Am Heart J. 2006;152:1096, e1099–1015.
  • 15
    Palazzuoli A, Silverberg DS, Iovine F, et al. Effects of beta-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome. Am Heart J. 2007;154:645, e649–615.
  • 16
    Silverberg DS, Wexler D, Blum M, Iaina A. The cardio renal anemia syndrome: correcting anemia in patients with resistant congestive heart failure can improve both cardiac and renal function and reduce hospitalizations. Clin Nephrol. 2003;60(Suppl 1):S93S102.
  • 17
    Silverberg DS, Wexler D, Blum M, et al. Effect of correction of anemia with erythropoietin and intravenous iron in resistant heart failure in octogenarians. Isr Med Assoc J. 2003;5:337339.
  • 18
    Silverberg DS, Wexler D, Sheps D, et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol. 2001;37:17751780.
  • 19
    Tehrani F, Dhesi P, Daneshvar D, et al. Erythropoiesis stimulating agents in heart failure patients with anemia: a meta-analysis. Cardiovasc Drugs Ther. 2009;23:511518.
  • 20
    McMurray JJ, Anand IS, Diaz R, et al. Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial. Eur J Heart Fail. 2009;11:795801.
  • 21
    Lang CC, Mancini DM. Non-cardiac comorbidities in chronic heart failure. Heart. 2007;93:665671.
  • 22
    Kim YR, Pyun WB, Shin GJ. Relation of anemia to echocardiographically estimated left ventricular filling pressure in hypertensive patients over 50 year-old. J Cardiovasc Ultrasound. 2010;18:8690.
  • 23
    Abramov D, He KL, Wang J, Burkhoff D, Maurer MS. The impact of extra cardiac comorbidities on pressure volume relations in heart failure and preserved ejection fraction. J Card Fail. 2011;17:547555.
  • 24
    van der Meer P, Voors AA, Lipsic E, et al. Erythropoietin in cardiovascular diseases. Eur Heart J. 2004;25:285291.
  • 25
    Cohen RS, Karlin P, Yushak M, et al. The effect of erythropoietin on exercise capacity, left ventricular remodeling, pressure-volume relationships, and quality of life in older patients with anemia and heart failure with preserved ejection fraction. Congest Heart Fail. 2010;16:96103.
  • 26
    Maurer MS, Teruya S, Chakraborty B, et al. Treating Anemia in Older Adults with Heart Failure with a Preserved Ejection Fraction (HFPEF) with Epoetin Alfa: single Blind Randomized Clinical Trial of Safety and Efficacy. Circ Heart Fail. 2012. [Epub ahead of print]
  • 27
    Schocken DD, Arrieta MI, Leaverton PE, Ross EA. Prevalence and mortality rate of congestive heart failure in the United States. J Am Coll Cardiol. 1992;20:301306.
  • 28
    Parker KP, Mitch WE, Stivelman JC, et al. Safety and efficacy of low-dose subcutaneous erythropoietin in hemodialysis patients. J Am Soc Nephrol. 1997;8:288293.
  • 29
    Teruya SL, Gil HR, Teresi JA, et al. Facilitating clinical trials of anemia in older adults: a point-of-care system to measure hemoglobin in the home and its agreement with a hospital core laboratory. J Am Geriatr Soc. 2009;57:23622364.
  • 30
    Papavassiliu T, Kuhl HP, Schroder M, et al. Effect of endocardial trabeculae on left ventricular measurements and measurement reproducibility at cardiovascular MR imaging. Radiology. 2005;236:5764.
  • 31
    Suga H, Sagawa K. Instantaneous pressure-volume relationships and their ratio in the excised, supported canine left ventricle. Circ Res. 1974;35:117126.
  • 32
    Kelly RP, Ting CT, Yang TM, et al. Effective arterial elastance as index of arterial vascular load in humans. Circulation. 1992;86:513521.
  • 33
    Klotz S, Dickstein ML, Burkhoff D. A computational method of prediction of the end-diastolic pressure-volume relationship by single beat. Nat Protoc. 2007;2:21522158.
  • 34
    Klotz S, Hay I, Dickstein ML, et al. Single-beat estimation of end-diastolic pressure-volume relationship: a novel method with potential for noninvasive application. Am J Physiol Heart Circ Physiol. 2006;291:H403H412.
  • 35
    Nishimura RA, Appleton CP, Redfield MM, et al. Noninvasive doppler echocardiographic evaluation of left ventricular filling pressures in patients with cardiomyopathies: a simultaneous Doppler echocardiographic and cardiac catheterization study. J Am Coll Cardiol. 1996;28:12261233.
  • 36
    Burkhoff D, Mirsky I, Suga H. Assessment of systolic and diastolic ventricular properties via pressure-volume analysis: a guide for clinical, translational, and basic researchers. Am J Physiol Heart Circ Physiol. Aug 2005;289:H501H512.
  • 37
    Richardson D. Clinical factors influencing sensitivity and response to epoetin. Nephrol Dial Transplant. 2002;17(Suppl 1):5359.
  • 38
    Rossert J, Gassmann-Mayer C, Frei D, McClellan W. Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients. Nephrol Dial Transplant. Mar 2007;22:794800.
  • 39
    Biesenbach G, Schmekal B, Eichbauer-Sturm G, Janko O. Erythropoietin requirement in patients with type 2 diabetes mellitus on maintenance hemodialysis therapy. Wien Klin Wochenschr. 2004;116:844848.
  • 40
    Chen HH, Tarng DC, Lee KF, et al. Epoetin alfa and darbepoetin alfa: effects on ventricular hypertrophy in patients with chronic kidney disease. J Nephrol. 2008;21:543549.
  • 41
    Pappas KD, Gouva CD, Katopodis KP, et al. Correction of anemia with erythropoietin in chronic kidney disease (stage 3 or 4): effects on cardiac performance. Cardiovasc Drugs Ther. 2008;22:3744.
  • 42
    Portoles J, Torralbo A, Martin P, et al. Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am J Kidney Dis. 1997;29:541548.
  • 43
    Ayus JC, Go AS, Valderrabano F, et al. Effects of erythropoietin on left ventricular hypertrophy in adults with severe chronic renal failure and hemoglobin <10 g/dL. Kidney Int. 2005;68:788795.
  • 44
    Hayashi T, Suzuki A, Shoji T, et al. Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis. 2000;35:250256.
  • 45
    Hampl H, Hennig L, Rosenberger C, et al. Effects of optimized heart failure therapy and anemia correction with epoetin beta on left ventricular mass in hemodialysis patients. Am J Nephrol. 2005;25:211220.
  • 46
    Low I, Grutzmacher P, Bergmann M, Schoeppe W. Echocardiographic findings in patients on maintenance hemodialysis substituted with recombinant human erythropoietin. Clin Nephrol. 1989;31:2630.
  • 47
    Parissis JT, Kourea K, Panou F, et al. Effects of darbepoetin alpha on right and left ventricular systolic and diastolic function in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am Heart J. 2008;155:751, e751–757.
  • 48
    Roger SD, McMahon LP, Clarkson A, et al. Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial. J Am Soc Nephrol. 2004;15:148156.
  • 49
    Grothues F, Smith GC, Moon JC, et al. Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. Am J Cardiol. 2002;90:2934.
  • 50
    Dewey M, Muller M, Eddicks S, et al. Evaluation of global and regional left ventricular function with 16-slice computed tomography, biplane cineventriculography, and two-dimensional transthoracic echocardiography: comparison with magnetic resonance imaging. J Am Coll Cardiol. 2006;48:20342044.
  • 51
    Unger EF, Thompson AM, Blank MJ, Temple R. Erythropoiesis-stimulating agents–time for a reevaluation. N Engl J Med. 2010;362:189192.
  • 52
    Solomon SD, Uno H, Lewis EF, et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med. 2010;363:11461155.